These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32083570)

  • 1. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
    Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
    Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
    Taylor DD; Gercel-Taylor C; Parker LP
    Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
    Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
    Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.
    Chatterjee M; Hurley LC; Levin NK; Stack M; Tainsky MA
    Cancer Biomark; 2017 Dec; 20(4):369-387. PubMed ID: 29125478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
    PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Fortner RT; Damms-Machado A; Kaaks R
    Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.